Naslov
Pancreatic cancer and nutrition

Autori
Mužina Mišić, Dubravka ; Zovak, Mario ; Čiček, Slaven

Izvornik
Biomedicine and Surgery (2459-816X) 1 (2017), 1; 10-15

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, stručni

Ključne riječi
cachexia ; malignant neoplasms ; enteral nutrition

Sažetak
Although there was a progress in surgical and oncological treatment of pancreatic cancer in a recent decade, pancreatic cancer remains a disease with a dismal prognosis, with 5-year survival of only 5 percent. Operable pancreatic cancer patients have better prognosis (around 25 percent are still alive after 5 years), but most of the patients are inoperable at the time of diagnosis. Considering low operability and higher tendency for weight loss and tumor-induced systemic inflammation, pancreatic cancer patients have high incidence of cachexia. Cachexia in cancer patients is associated with lower quality of life, shorter survival and lower tolerance of anti-tumor therapy. All pancreatic cancer patients, both with operable, inoperable or disseminated disease, should be screened and treated for cachexia. Nowadays, treatment of cachexia should me multimodal and multidisciplinary.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA